ESCs provide a key to new blood supply

When scientists talk about the potential embryonic stem cells have in treating disease, they often focus on a relatively distant horizon when new therapies can be developed to cure some of the world's most complex diseases. But the New York Times points to a not-so-distant time when ESCs may be used to create a virtually unlimited supply of blood free from the risk of disease presented by donors.

To get there, the Defense Advanced Research Projects Agency--a key player in biomedical research--has begun a blood pharming project that will explore just how feasible that can be. The work has been advanced by Advanced Cell Technology, a stem cell company that has a troubled financial record, but a history of high-profile breakthroughs. They recently reported making 10 billion to 100 billion red cells after starting with a platelet of ESCs.

"It's the first time to my knowledge that anyone has been able to produce these on a sufficient scale to talk of using them for transfusion purposes," the co-author of the paper, Dr. George Honig of the University of Illinois at Chicago, tells the NYT.

- read the article in the New York Times

Related Articles:
ACT says it has found key to limitless blood supply
Stem cell revolutionaries take on big challenges
In research, stem cells make another breakthrough
What's in store for stem cell treatments?